The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PF-07284892 in Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04800822
Recruitment Status : Active, not recruiting
First Posted : March 16, 2021
Last Update Posted : April 30, 2024
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: PF-07284892 Drug: lorlatinib Drug: binimetinib Biological: cetuximab Drug: encorafenib Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Actual Study Start Date : March 17, 2021
Estimated Primary Completion Date : June 18, 2024
Estimated Study Completion Date : November 29, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PF-07284892 monotherapy
Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558
Experimental: PF-07284892 in combination with lorlatinib (Part 2)
Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Drug: lorlatinib
lorlatinib
Other Name: Lorbrena; PF-06463922, Lorviqua
Experimental: Expansion Phase (Cohort 1)
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Drug: lorlatinib
lorlatinib
Other Name: Lorbrena; PF-06463922, Lorviqua
Experimental: Expansion Phase (Cohort 2)
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Drug: lorlatinib
lorlatinib
Other Name: Lorbrena; PF-06463922, Lorviqua
Experimental: Expansion Phase (Cohort 3)
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Biological: cetuximab
cetuximab
Other Name: Erbitux

Drug: encorafenib
encorafenib
Other Name: Braftovi, PF-07263896, LGX818
Experimental: Expansion Phase (Cohort 4)
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Biological: cetuximab
cetuximab
Other Name: Erbitux

Drug: encorafenib
encorafenib
Other Name: Braftovi, PF-07263896, LGX818
Experimental: Expansion Phase (Cohort 5)
PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Drug: binimetinib
binimetinib
Other Name: Mektovi, PF-06811462, MEK162
Experimental: PF-07284892 in combination with encorafenib and cetuximab (Part 2)
Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Biological: cetuximab
cetuximab
Other Name: Erbitux

Drug: encorafenib
encorafenib
Other Name: Braftovi, PF-07263896, LGX818
Experimental: PF-07284892 in combination with binimetinib (Part 2)
Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
 Drug: PF-07284892
PF-07284892
Other Name: ARRY-558

Drug: binimetinib
binimetinib
Other Name: Mektovi, PF-06811462, MEK162


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs) [ Time Frame: Cycle 1 (21 days) ]
    DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with lorlatinib, encorafenib + cetuximab, or binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study

  2. Part 1 and Part 2- Number of participants with treatment-emergent adverse events (AEs) [ Time Frame: Baseline up to 30 days after last dose of study medication ]
    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

  3. Part 1 and Part 2 - Number of participants with clinically significant change from baseline in laboratory abnormalities [ Time Frame: Baseline up to 30 days after last dose of study treatment ]
    Laboratory abnormalities as characterized by type, frequency, severity, and timing

  4. Part 1 and Part 2 - Number of dose interruptions, dose modifications, and discontinuations due to AEs [ Time Frame: Baseline up to 30 days after the last dose of study medication ]
    Incidence of dose interruptions, dose modifications, and discontinuations due to AEs

  5. Part 3- Overall response [ Time Frame: Baseline to up to 2 years ]
    Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)


Secondary Outcome Measures :
  1. Part 1 and Part 2- Maximum plasma concentration (Cmax) of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; end of treatment (EOT) ]
    single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters

  2. Part 1 and Part 2- Time to reach maximum plasma concentration (Tmax) of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT ]
    Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) pharmacokinetic parameters

  3. Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT ]
    Single dose PK parameter

  4. Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUCinf) of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT ]
    Single dose and multiple dose (assuming steady state is achieved) PK parameter

  5. Part 1 and Part 2- Metabolite ratio of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT ]
    Single dose PK parameter

  6. Part 1 and Part 2- Area under the plasma concentration-time curve from 0 to 24 (AUC24) or 48 hours (AUC48) of PF-07284892 and metabolite [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT ]
    Multiple dose (assuming steady state is achieved) PK parameter

  7. Part 1 and Part 2- Overall response [ Time Frame: Baseline to up to 2 years ]
    Response will be evaluated via radiographical tumor assessments by RECIST v1.1

  8. Part 2- Duration of Response (DOR) [ Time Frame: Baseline to up to 2 years ]
    Time from the first documentation of objective response to the first documentation of objective progressive disease, relapse or to death due to any cause


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years at the time of informed consent
  • Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor. Participants with ROS-positive NSCLC are also eligible for Part 1 and 2 (Other ROS1-positive solid tumors may be considered after discussion with the sponsor).
  • Documentation evidence of biomarker mutation status
  • Part 3:

ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort 1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no prior lorlatinib (Cohort 3).

BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6).

RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC (Cohort 7).

Exclusion Criteria:

  • Brain metastasis larger than 4 cm
  • Active malignancy within 3 years
  • Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to start of study treatment. Antibody based agents within 4 weeks prior to start of study treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study treatment.
  • For participants who may get lorlatinib or encorafenib on study, history of interstitial lung disease
  • For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04800822


Locations
Show Show 18 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04800822    
Other Study ID Numbers: C4481001
2022-502431-18-00 ( Registry Identifier: CTIS (EU) )
2022-003166-21 ( EudraCT Number )
SHP2 ( Other Identifier: Alias Study Number )
First Posted: March 16, 2021    Key Record Dates
Last Update Posted: April 30, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
colorectal cancer
non-small cell lung cancer
B-type Raf proto-oncogene (BRAF) mutation
Ras mutation
 anaplastic lymphoma kinase (ALK)-positive
neurofibromatosis type 1 (NF1)
ROS1
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Cetuximab
Antineoplastic Agents, Immunological
Antineoplastic Agents